RxDoctor Payments Data

Katherine Little, APRN

Psychiatric/Mental Health · Lafayette, LANPI 1588989230

Payments from drug & device makers

$2,228in general payments, 2019–2025

Across 123 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$538
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$310
  • Alkermes, Inc.$299
  • Lundbeck LLC$263
  • Teva Pharmaceuticals USA, Inc.$152
  • Neurocrine Biosciences, Inc.$123
  • plus $541 from 11 others

What the payments were for

  • Food & beverage$2,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,228 in reported general payments places this provider in the 60th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$108,970
Medicare patients
582
Services billed
1,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate35$100,819
IngrezzaValbenazine Tosylate20$83,275
RexultiBrexpiprazole91$81,247
VraylarCariprazine Hcl29$41,992
AristadaAripiprazole Lauroxil13$35,009
Chlorpromazine Hcl68$7,515
Oxcarbazepine165$6,226
TrintellixVortioxetine Hydrobromide21$5,016
Paliperidone ErPaliperidone53$4,160
Clozapine49$3,215
Quetiapine Fumarate247$3,032
Asenapine Maleate16$2,920
Doxepin Hcl130$2,851
Lurasidone Hcl49$2,758
Divalproex Sodium98$2,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$118$100,81935 claims
Neurocrine Biosciences, Inc.Ingrezza$123$83,27520 claims
Otsuka America Pharmaceutical, Inc.Rexulti$107$81,24791 claims
AbbVieVraylar$538$41,99229 claims
Alkermes, Inc.Aristada$299$35,00913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$46$5,01621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →